1. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?

   • Ya-Nan Jin
   • Hui-Jiao Cao
   • Liang-Ping Xia

   Original Article – Clinical Oncology 07 October 2021 Pages: 2569 - 2579

   

2. Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma

   • Felix Schriegel
   • Sabine Taschner-Mandl
   • Karoline Ehlert

   Original Article – Clinical Oncology Open access 08 October 2021 Pages: 2581 - 2588

   

3. Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study

   • Hao Wei
   • Xiaojuan Zhou
   • Yongmei Liu

   Original Article – Clinical Oncology 20 October 2021 Pages: 2589 - 2598

   

4. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

   • Samantha O‘Hagan Henderson
   • Jochen J. Frietsch
   • Jochen Casper

   Original Article – Clinical Oncology Open access 21 October 2021 Pages: 2599 - 2609

   

5. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial

   • Martina Broecker-Preuss
   • Nina Becher-Boveleth
   • Ulrich Dührsen

   Original Article – Clinical Oncology Open access 27 October 2021 Pages: 2611 - 2621

   

6. Functional gland-preserving surgery for submandibular gland pleomorphic adenoma

   • Jong-Lyel Roh

   Original Article – Clinical Oncology 27 October 2021 Pages: 2623 - 2629

   

7. Natural history of Von Hippel–Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study

   • Jie Wang
   • Lei Zhang
   • Liqun Zhou

   Original Article – Clinical Oncology 28 October 2021 Pages: 2631 - 2641

   

8. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

   • Lihua Yu
   • Lulu Huang
   • Lihua Yang

   Original Article – Clinical Oncology Open access 01 November 2021 Pages: 2643 - 2652

   

9. TCF-1⁺ PD-1⁺ CD8⁺T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients

   • Xia Fang
   • Gang Wu
   • Shaoyong Gao

   Original Article – Clinical Oncology 02 November 2021 Pages: 2653 - 2660

   

10. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer

    • Xuetian Gao
    • Ling Peng
    • Jisheng Li

    Original Article – Clinical Oncology 08 November 2021 Pages: 2661 - 2671

    

11. Protein expression of prognostic genes in primary melanoma and benign nevi

    • T. Gambichler
    • J. Elfering
    • L. Susok

    Original Article – Clinical Oncology Open access 10 November 2021 Pages: 2673 - 2680

    

12. Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules

    • Jianzhu Xie
    • Zheng Ruan
    • Qian Huang

    Original Article – Clinical Oncology 17 November 2021 Pages: 2681 - 2692

    

13. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera

    • Carl C. Crodel
    • Kathleen Jentsch-Ullrich
    • Florian H. Heidel

    Original Article – Clinical Oncology Open access 22 November 2021 Pages: 2693 - 2705

    

14. Self-efficacy in relation to the use of complementary and alternative medicine, lifestyle choices and cancer aetiology

    • Lena Josfeld
    • Lara Krüger
    • Jutta Hübner

    Original Article – Clinical Oncology Open access 23 November 2021 Pages: 2707 - 2715

    

15. Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?

    • Zelin Ma
    • Zezhou Wang
    • Haiquan Chen

    Original Article – Cancer Research 07 May 2022 Pages: 2717 - 2722

    

16. Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status

    • Josien C. A. Jenniskens
    • Kelly Offermans
    • Piet A. van den Brandt

    Original Article – Cancer Research Open access 11 May 2022 Pages: 2723 - 2742

    

17. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model

    • Said Ahmed Bahwal
    • Jane J. Chen
    • Xingwang Zhou

    Original Article – Cancer Research 12 May 2022 Pages: 2743 - 2757

    

18. BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

    • Joseph Kauer
    • Melanie Märklin
    • Jonas S. Heitmann

    Original Article – Cancer Research Open access 13 May 2022 Pages: 2759 - 2771

    

19. Deep learning combined with radiomics for the classification of enlarged cervical lymph nodes

    • Wentao Zhang
    • Jian Peng
    • Shengsheng Xu

    Original Article – Cancer Research 13 May 2022 Pages: 2773 - 2780

    

20. Trends of cancer mortality in Xi’an City, China: 2005–2020

    • Ning Chen
    • Xiao-Yu Zhang
    • Yu-Xiang Yan

    Original Article – Cancer Research 14 May 2022 Pages: 2781 - 2792

    

21. Expression changes in ion channel and immunity genes are associated with glioma-related epilepsy in patients with diffuse gliomas

    • Lianwang Li
    • Chuanbao Zhang
    • Tao Jiang

    Original Article – Cancer Research 18 May 2022 Pages: 2793 - 2802

    

22. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer

    • Xue Liu
    • Changsheng Ma
    • Judong Luo

    Original Article – Cancer Research 20 May 2022 Pages: 2803 - 2814

    

23. Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases

    • Robert Damm
    • Maciej Pech
    • Borna Relja

    Original Article – Cancer Research Open access 21 May 2022 Pages: 2815 - 2826

    

24. Evaluating risk factors for lung cancer among never-smoking individuals using two Australian studies

    • Elvin S. Cheng
    • Marianne F. Weber
    • Xue Qin Yu

    Original Article – Cancer Research Open access 27 May 2022 Pages: 2827 - 2840

25. NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

    • Takeshi Kajiwara
    • Tomohiro Nishina
    • Ichinosuke Hyodo

    Original Article – Cancer Research 27 May 2022 Pages: 2841 - 2854

    

26. Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database

    • Dong-sook Kim
    • Hyun Jung Kim
    • Hyeong Sik Ahn

    Original Article – Cancer Research 04 June 2022 Pages: 2855 - 2865

    

27. The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer

    • Chun Liu
    • Chenxi Hu
    • Xiaodong Jiang

    Original Article – Cancer Research 07 June 2022 Pages: 2867 - 2879

    

28. Brain infiltration of breast cancer stem cells is facilitated by paracrine signaling by inhibitor of differentiation 3 to nuclear respiratory factor 1

    • Jayanta K. Das
    • Alok Deoraj
    • Quentin Felty

    Original Article – Cancer Research 09 June 2022 Pages: 2881 - 2891

    

29. The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer

    • Monyse de Nóbrega
    • Mariana Bisarro dos Reis
    • Ilce Mara de Syllos Cólus

    Review – Cancer Research 04 August 2022 Pages: 2893 - 2910

    

30. Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review

    • Hongyan Liao
    • Jiang Yu
    • Qin Zheng

    Review – Clinical Oncology 06 August 2022 Pages: 2911 - 2919

    

31. Does first-line immunotherapy impact the efficacy of later treatments: a discussion on the use of second progression-free survival as a research endpoint

    • Zhening Zhang
    • Lin Shen
    • Zhi Peng

    Correspondence 14 June 2022 Pages: 2921 - 2924

32. What would one of the greatest natural scientists and educators of the eighteenth century, Georg Christoph Lichtenberg, say about the current therapy management of patients with penile cancer?

    • Florian A. Distler
    • Sascha Pahernik
    • Matthias May

    Correspondence 21 June 2022 Pages: 2925 - 2927

    

33. Two cases of EBV infection preceding lymphoma

    • Jonas Saal
    • Busher Aboudan
    • Annkristin Heine

    Correspondence Open access 22 June 2022 Pages: 2929 - 2932

    

34. A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma

    • Chujie Bai
    • Lu Zhang
    • Zhengfu Fan

    Correspondence 07 August 2022 Pages: 2933 - 2937

    

35. Answer to the letter by Frass et al. to our systematic review

    • J. Hübner
    • Ch. Lübbers

    Correspondence Open access 09 August 2022 Pages: 2939 - 2941

36. Homeopathy effects in patients during oncological treatment

    • Michael Frass
    • Konstantin Zhigalov
    • Petra Weiermayer

    Correspondence 09 August 2022 Pages: 2943 - 2944